NetraMark’s AI Platform Gains Recognition in npj Digital Medicine

NetraMark Holdings ( (TSE:AIAI) ) just unveiled an update.

NetraMark Holdings Inc. announced the acceptance of its peer-reviewed paper in npj Digital Medicine, showcasing its NetraAI platform’s ability to enhance clinical trials through explainable AI-driven precision analytics. The study, which involved collaboration with the National Institute of Mental Health, highlights the platform’s capacity to identify patient subpopulations and improve trial outcomes, potentially impacting regulatory science and clinical decision-making.

More about NetraMark Holdings

NetraMark Holdings Inc. is a leader in the development of Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry. The company utilizes a novel topology-based algorithm to analyze patient datasets, enabling the segmentation of diseases and classification of patients based on drug sensitivity and treatment efficacy.

YTD Price Performance: 3.92%

Average Trading Volume: 47,802

Technical Sentiment Signal: Hold

Current Market Cap: C$91M

Find detailed analytics on AIAI stock on TipRanks’ Stock Analysis page.